FDA label e4deee06-e36f-2dc3-e053-2995a90ad511

5 WARNINGS AND PRECAUTIONS • Hypersensitivity Reactions : Hypersensitivity reactions, including anaphylaxis and bronchospasm have been reported in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists. ( 5.1 ) • QT Prolongation and Torsade de Pointes : QT prolongation occurs in a dose-dependent manner. Cases of Torsade de Pointes have been reported. Avoid ondansetron injection in patients with congenital long QT syndrome. ( 5.2 ) • Serotonin Syndrome : Serotonin syndrome has been reported with 5-HT 3 receptor agonists alone but particularly with concomitant use of serotonergic drugs. ( 5.3 ) • Masking of Progressive Ileus and/or Gastric Distention Following Abdominal Surgery or Chemotherapy-Induced Nausea and Vomiting : Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. ( 5.4 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis and bronchospasm, have been reported in patients who have exhibited hypersensitivity to other selective 5-HT 3 receptor antagonists. 5.2 QT Prolongation Ondansetron prolongs the QT interval in a dose-dependent manner [see Clinical Pharmacology (12.2) ] . In addition, postmarketing cases of Torsade de Pointes have been reported in patients using ondansetron. Avoid ondansetron injection in patients with congenital long QT syndrome. Electrocardiogram (ECG) monitoring is recommended in patients with electrolyte abnormalities (e.g., hypokalemia or hypomagnesemia), congestive heart failure, bradyarrhythmias, or patients taking other medicinal products that lead to QT prolongation. 5.3 Serotonin Syndrome The development of serotonin syndrome has been reported with 5-HT 3 receptor antagonists. Most reports have been associated with concomitant use of serotonergic drugs (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors, mirtazapine, fentanyl, lithium, tramadol, and intravenous methylene blue). Some of the reported cases were fatal. Serotonin syndrome occurring with overdose of ondansetron alone has also been reported. The majority of reports of serotonin syndrome related to 5-HT 3 receptor antagonist use occurred in a post-anesthesia care unit or an infusion center. Symptoms associated with serotonin syndrome may include the following combination of signs and symptoms: mental status changes (e.g., agitation, hallucinations, delirium, and coma), autonomic instability (e.g., tachycardia, labile blood pressure, dizziness, diaphoresis, flushing, hyperthermia), neuromuscular symptoms (e.g., tremor, rigidity, myoclonus, hyperreflexia, incoordination), seizures, with or without gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea). Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of ondansetron injection and other serotonergic drugs. If symptoms of serotonin syndrome occur, discontinue ondansetron injection and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ondansetron injection is used concomitantly with other serotonergic drugs [see Drug Interactions (7.5) , Overdosage (10) ]. 5.4 Masking of Progressive Ileus and Gastric Distension The use of ondansetron injection in patients following abdominal surgery or in patients with chemotherapy-induced nausea and vomiting may mask a progressive ileus and gastric distention. Monitor for decreased bowel activity, particularly in patients with risk factors for gastrointestinal obstruction. Ondansetron injection is not a drug that stimulates gastric or intestinal peristalsis. It should not be used instead of nasogastric suction.

6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity reactions [see Warnings and Precautions (5.1) ] • QT prolongation [see Warnings and Precautions (5.2) ] • Serotonin syndrome [see Warnings and Precautions (5.3) ] • Masking of progressive ileus and gastric distention [see Warnings and Precautions (5.4) ] Chemotherapy-Induced Nausea and Vomiting : • The most common adverse reactions (≥7%) in adults are diarrhea, headache, and fever. ( 6.1 ) Postoperative Nausea and Vomiting : • The most common adverse reaction (≥10%) which occurs at a higher frequency compared with placebo in adults is headache. ( 6.1 ) • The most common adverse reaction (≥2%) which occurs at a higher frequency compared with placebo in pediatric patients aged 1 to 24 months is diarrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Avet Pharmaceuticals Inc. at 1-866-901-DRUG (3784) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The following adverse reactions have been reported in clinical trials of adult patients treated with ondansetron, the active ingredient of intravenous ondansetron injection across a range of dosages. A causal relationship to therapy with ondansetron injection was unclear in many cases. Chemotherapy-induced Nausea and Vomiting Table 2: Adverse Reactions Reported in >5% of Adult Patients Who Received Ondansetron at a Dosage of Three 0.15-mg/kg Doses Adverse Reaction Number of Adult Patients With Reaction Ondansetron Injection 0.15 mg/kg x 3 (n = 419) Metoclopramide (n = 156) Placebo (n = 34) Diarrhea 16% 44% 18% Headache 17% 7% 15% Fever 8% 5% 3% Cardiovascular: Rare cases of angina (chest pain), electrocardiographic alterations, hypotension, and tachycardia have been reported. Gastrointestinal: Constipation has been reported in 11% of chemotherapy patients receiving multiday ondansetron. Hepatic: In comparative trials in cisplatin chemotherapy patients with normal baseline values of aspartate transaminase (AST) and alanine transaminase (ALT), these enzymes have been reported to exceed twice the upper limit of normal in approximately 5% of patients. The increases were transient and did not appear to be related to dose or duration of therapy. On repeat exposure, similar transient elevations in transaminase values occurred in some courses, but symptomatic hepatic disease did not occur. Integumentary: Rash has occurred in approximately 1% of patients receiving ondansetron. Neurological: There have been rare reports consistent with, but not diagnostic of, extrapyramidal reactions in patients receiving ondansetron injection, and rare cases of grand mal seizure. Other: Rare cases of hypokalemia have been reported. Postoperative Nausea and Vomiting The adverse reactions in Table 3 have been reported in ≥2% of adults receiving ondansetron at a dosage of 4 mg intravenous over 2 to 5 minutes in clinical trials. Table 3: Adverse Reactions Reported in ≥2% (and with greater frequency than the placebo group) of Adult Patients Receiving Ondansetron at a Dosage of 4 mg Intravenous Over 2 to 5 Minutes Adverse Reaction a,b Ondansetron Injection 4 mg Intravenous (n = 547) Placebo (n = 547) Headache 92 (17%) 77 (14%) Drowsiness/Sedation 44 (8%) 37 (7%) Injection-site reaction 21 (4%) 18 (3%) Fever 10 (2%) 6 (1%) Cold sensation 9 (2%) 8 (1%) Pruritus 9 (2%) 3 (< 1%) Paresthesia 9 (2%) 2 (< 1%) a Adverse reactions: Rates of these reactions were not significantly different in the ondansetron and placebo groups. b Patients were receiving multiple concomitant perioperative and postoperative medications. Pediatric Use: Rates of adverse reactions were similar in both the ondansetron and placebo groups in pediatric patients receiving ondansetron (a single 0.1-mg/kg dose for pediatric patients weighing 40 kg or less, or 4 mg for pediatric patients weighing more than 40 kg) administered intravenously over at least 30 seconds. Diarrhea was seen more frequently in patients taking ondansetron injection (2%) compared with placebo (<1%) in the 1-month to 24-month age-group. These patients were receiving multiple concomitant perioperative and postoperative medications. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ondansetron. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The reactions have been chosen for inclusion due to a combination of their seriousness, frequency of reporting, or potential causal connection to ondansetron. Cardiovascular Arrhythmias (including ventricular and supraventricular tachycardia, premature ventricular contractions, and atrial fibrillation), bradycardia, electrocardiographic alterations (including second-degree heart block, QT/QTc interval prolongation, and ST segment depression), palpitations, and syncope. Rarely and predominantly with intravenous ondansetron, transient ECG changes, including QT/QTc interval prolongation have been reported [see Warnings and Precautions (5.2) ] . General Flushing: Rare cases of hypersensitivity reactions, sometimes severe (e.g., anaphylactic reactions, angioedema, bronchospasm, cardiopulmonary arrest, hypotension, laryngeal edema, laryngospasm, shock, shortness of breath, stridor) have also been reported. A positive lymphocyte transformation test to ondansetron has been reported, which suggests immunologic sensitivity to ondansetron. Hepatobiliary Liver enzyme abnormalities have been reported. Liver failure and death have been reported in patients with cancer receiving concurrent medications, including potentially hepatotoxic cytotoxic chemotherapy and antibiotics. Local Reactions Pain, redness, and burning at site of injection. Lower Respiratory Hiccups. Neurological Oculogyric crisis, appearing alone, as well as with other dystonic reactions. Transient dizziness during or shortly after intravenous infusion. Skin Urticaria, Stevens-Johnson syndrome, and toxic epidermal necrolysis. Eye Disorders Cases of transient blindness, predominantly during intravenous administration, have been reported. These cases of transient blindness were reported to resolve within a few minutes up to 48 hours. Transient blurred vision, in some cases associated with abnormalities of accommodation, has also been reported.

<table cellspacing="0" cellpadding="0" border="0" width="100%"><col width="19.96%"/><col width="36.2%"/><col width="27.54%"/><col width="16.3%"/><tbody><tr styleCode="Botrule"><td rowspan="2" styleCode="Lrule Rrule" valign="bottom"> <content styleCode="bold">Adverse Reaction</content></td><td colspan="3" styleCode="Rrule" valign="middle"> <content styleCode="bold">Number of Adult Patients With Reaction</content></td></tr><tr styleCode="Botrule"><td align="center" styleCode="Lrule Rrule" valign="bottom"> <content styleCode="bold">Ondansetron Injection</content> <content styleCode="bold">0.15 mg/kg x 3</content> <content styleCode="bold">(n = 419)</content></td><td align="center" styleCode="Rrule" valign="bottom"> <content styleCode="bold">Metoclopramide</content> <content styleCode="bold">(n = 156)</content></td><td align="center" styleCode="Rrule" valign="bottom"> <content styleCode="bold">Placebo</content> <content styleCode="bold">(n = 34)</content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Diarrhea </td><td align="center" styleCode="Rrule" valign="middle"> 16% </td><td align="center" styleCode="Rrule" valign="middle"> 44% </td><td align="center" styleCode="Rrule" valign="middle"> 18% </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Headache </td><td align="center" styleCode="Rrule" valign="middle"> 17% </td><td align="center" styleCode="Rrule" valign="middle"> 7% </td><td align="center" styleCode="Rrule" valign="middle"> 15% </td></tr><tr><td styleCode="Lrule Rrule" valign="middle"> Fever </td><td align="center" styleCode="Rrule" valign="middle"> 8% </td><td align="center" styleCode="Rrule" valign="middle"> 5% </td><td align="center" styleCode="Rrule" valign="middle"> 3% </td></tr></tbody></table>

<table cellspacing="0" cellpadding="0" border="0" width="100%"><col width="33.78%"/><col width="34.68%"/><col width="31.54%"/><tbody><tr styleCode="Botrule"><td align="center" styleCode="Lrule Rrule" valign="bottom"> <content styleCode="bold">Adverse Reaction</content><content styleCode="bold">^a,b</content></td><td styleCode="Rrule" valign="middle"> <content styleCode="bold"/> <content styleCode="bold"> Ondansetron Injection 4 mg </content> <content styleCode="bold">Intravenous </content><content styleCode="bold">(n = 547)</content> </td><td align="center" styleCode="Rrule" valign="bottom"><content styleCode="bold"/> <content styleCode="bold"> Placebo (n = 547) </content></td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Headache </td><td align="center" styleCode="Rrule" valign="middle"> 92 (17%) </td><td align="center" styleCode="Rrule" valign="middle"> 77 (14%) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Drowsiness/Sedation </td><td align="center" styleCode="Rrule" valign="middle"> 44 (8%) </td><td align="center" styleCode="Rrule" valign="middle"> 37 (7%) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Injection-site reaction </td><td align="center" styleCode="Rrule" valign="middle"> 21 (4%) </td><td align="center" styleCode="Rrule" valign="middle"> 18 (3%) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Fever </td><td align="center" styleCode="Rrule" valign="middle"> 10 (2%) </td><td align="center" styleCode="Rrule" valign="middle"> 6 (1%) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Cold sensation </td><td align="center" styleCode="Rrule" valign="middle"> 9 (2%) </td><td align="center" styleCode="Rrule" valign="middle"> 8 (1%) </td></tr><tr styleCode="Botrule"><td styleCode="Lrule Rrule" valign="middle"> Pruritus </td><td align="center" styleCode="Rrule" valign="middle"> 9 (2%) </td><td align="center" styleCode="Rrule" valign="middle"> 3 (&lt; 1%) </td></tr><tr><td styleCode="Lrule Rrule" valign="middle"> Paresthesia </td><td align="center" styleCode="Rrule" valign="middle"> 9 (2%) </td><td align="center" styleCode="Rrule" valign="middle"> 2 (&lt; 1%) </td></tr></tbody></table>